Hansa Biopharma ABOSTO:HNSA -0.85%50 Current Ratio is 3.63 as of Mar. 2026, which is 42% below its 10-year median of 6.23. GuruFocus rates OSTO:HNSA with a GF Score™ of 50/100 and a GF Value™ of kr24.52 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Hansa Biopharma AB ranks worse than 52.48% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hansa Biopharma AB's current ratio for the quarter that ended in Mar. 2026 was 3.63.
Hansa Biopharma AB has a current ratio of 3.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Hansa Biopharma AB's Current Ratio or its related term are showing as below:
OSTO:HNSA'
s Current Ratio Range Over the Past 10 Years
Min: 1.11 Med: 6.23 Max: 17.76
Current: 3.63
During the past 13 years, Hansa Biopharma AB's highest Current Ratio was 17.76. The lowest was 1.11. And the median was 6.23.
OSTO:HNSA's Current Ratio is ranked worse than 52.48% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs OSTO:HNSA: 3.63
Hansa Biopharma AB (OSTO:HNSA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hansa Biopharma AB Current Ratio Related Terms
Hansa Biopharma AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) has a Current Ratio of 3.63 as of Mar. 2026. This is 42% below median its historical median of 6.23. Over the past decade, Hansa Biopharma AB's Current Ratio has ranged from 1.11 to 17.76. According to the industry distribution chart, Hansa Biopharma AB ranks #741 out of 1412 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Hansa Biopharma AB's Current Ratio too high?
Hansa Biopharma AB's current Current Ratio of 3.63 is 42% below median its 10-year median of 6.23. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 17.76. The Biotechnology industry median Current Ratio is 3.90. Hansa Biopharma AB's value of 3.63 is 6.9% below this industry median. Based on the distribution chart, Hansa Biopharma AB ranks #741 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hansa Biopharma AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #741 out of 1412 companies for Current Ratio. This places Hansa Biopharma AB in the lower half of its industry. The industry median Current Ratio is 3.90. Hansa Biopharma AB's value of 3.63 is 6.9% below this benchmark. Historically, Hansa Biopharma AB's own Current Ratio has ranged from 1.11 to 17.76 over the past decade. While the company's 10-year median is 6.23 vs. the industry median of 3.90, Hansa Biopharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansa Biopharma AB's current Current Ratio of 3.63 is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current Current Ratio is 3.63, which is 42% below median its own 10-year median of 6.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.52, compared to a current price of kr35.10 — trading 43.1% above its estimated fair value. The current Current Ratio is 3.63, which is 42% below median its 10-year median of 6.23 and 6.9% below the Biotechnology industry median of 3.90. Hansa Biopharma AB's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Current Ratio is 3.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr35.10 is trading 43.1% above its estimated GF Value™ of kr24.52.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Current Ratio: 3.63 (42% below median its 10-year median of 6.23)
GF Value™: kr24.52 vs. price of kr35.10 (43.1% above fair value)
Industry Position: 6.9% below the Biotechnology median (#741 of 1412)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
50GF Score
Get the complete analysis for OSTO:HNSA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
